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Pneumococcal conjugate vaccine (PCV) has the potential to interact with other vaccines containing diphtheria
toxin-like antigens (such as those found in the DTP vaccine) upon sequential administration. This is attributed to
the similarity of the diphtheria toxoid antigen to the carrier protein used to make PCV, (known as cross reactive
material [CRM]) to diphtheria toxin 197 or CRM197. The interaction could lead to enhanced immunogenicity of PCV
as a result of a phenomenon called carrier priming, whereby DTP is given some weeks before the first dose of PCV.
This phenomenon could be implemented in the immunisation schedule in developing countries and among
vulnerable populations to enhance the immunogenicity of PCV, reduce the number of doses required, and produce
a more cost-effective immunisation program in developing countries.
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Streptococcus pneumoniae is a leading cause of pneumo-
nia and death in children worldwide [1]. It is estimated
that 14.5 million episodes of serious pneumococcal
disease occur each year in children aged less than five
years, resulting in at least 500,00 deaths, almost all of
which occur in low- and middle-income countries [2].
Vaccination has proved very successful in the control of
pneumococcal disease in many developing countries and
there is growing evidence for herd protection. For
example, in The Gambia, infant vaccination has reduced
vaccine-type pneumococcal carriage not only among
vaccinated children but also among non-vaccinated
older children and adults, indicating a substantial herd
effect [3]. However, not all countries have introduced
vaccination of infants as implementation is limited by
the high cost of the vaccine [4]. The cost of one dose of
pneumococcal conjugate vaccine (PCV) can be very high
in developed countries (> $100) [5]. The best subsidised
price for resource-poor countries has been brought* Correspondence: mohamed.tashani@health.nsw.gov.au
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cost of all other pediatric vaccines combined (HepB,
BCG, OPV, DPT-Hib, and Measles) [7]. Therefore, there
is intense interest in reducing the cost of vaccination
against pneumococcal disease in young children through
eg. shorter schedules of one or two doses instead of
three doses [8].
The use of the 3 + 0 schedule is supported by
randomised controlled clinical trials for prevention of
pneumonia and invasive pneumococcal disease (IPD)
in developing countries [9], and has been recom-
mended by WHO. However, after more than a decade
of using PCV in many developed countries, evidence
consistently demonstrates strong herd immunity; most
vaccine-type pneumococcal disease is close to elimin-
ation in children irrespective of individual vaccination
status [10]. Consequently, a “1 + 1” schedule (where a
booster dose is given in second year of life) has been
promoted for use in developing countries where the im-
munisation program is mature (implemented for few
years) and vaccine-type carriage is largely eliminated in
the community [11]. In such mature vaccine programmes,
individual protection may not be required because the
probability of exposure to vaccine-type infection has
become very low [10]. Therefore, a “1 + 1” schedule couldle is distributed under the terms of the Creative Commons Attribution 4.0
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erably reduced cost [8]. Long-term protection against IPD
by PCV depends on a combination of persistence of
protective serum antibody levels, immunological memory,
and herd immunity [12]. Additionally, and importantly,
we suggest consideration of the use of carrier priming to
enhance the immunogenicity, especially of the first PCV
dose. Carrier priming is defined as an improved antibody
response to a carbohydrate portion of a glycoconjugate
vaccine because an individual has been previously primed
with the carrier protein [13].
The 13-valent PCV utilises carrier protein cross-
reacting material 197 (CRM197) of diphtheria toxin,
which is antigenically similar to the diphtheria toxin in
DTP. It is believed that priming via the carrier molecule
enhances the response to conjugate vaccines by increas-
ing the number of carrier-specific T lymphocytes; these
can provide the necessary support for the expansion and
differentiation of polysaccharide specific B lymphocytes
[14]. Several studies have found that prior receipt of
tetanus/diphtheria containing vaccine such as DTP in
infants who are then administered conjugate vaccine can
lead to rapid and earlier onset of clinical protection
against the disease [15-17]. In developing countries, the
risk of IPD peaks in the first few months of life and the
current vaccine schedule is 6, 10 and 14 weeks. We
propose evaluation of a schedule that offers the first PCV
at ten weeks of age after prior administration of DTP
vaccine at six weeks to take advantage of carrier priming
[16]. If adequate priming occurs, a reduced schedule
(where first PCV is given after DTP) may be sufficient and
more cost-effective, particularly for resource poor settings
with mature immunisation programs.
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